Scientists had been waiting for more details about the two vaccini, even though they already are being used in many countries, and one recently won the backing of the Organizzazione mondiale della sanità per uso di emergenza.
Il rapporto, published online in the Journal of the American Medical Association, concluded the two vaccini are about 73% e 78% efficace, as Sinopharm has previously claimed.
Researchers from Sinopharm and its local partners in the Medio Oriente say the trial involved around 40,380 participants with the company’s two vaccini — one developed by the Wuhan Institute of Biological Products and the other by the Beijing Institute of Biological Products — and a placebo. The trial was carried out in four countries — Bahrain, gli Emirati Arabi Uniti, Egypt and Jordan. tuttavia, the study provided data for just Bahrain and the UAE.